Amarin calls Hikma's drug label arguments 'idiosyncratic,' urges high court to decline case
The US Supreme Court should decline to review a generic drug labeling fight between Amarin and Hikma Pharmaceuticals because the case is “intensely fact-bound” and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
